about
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in UgandaClinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient dataPolymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan ChildrenTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaArtemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan childrenArtemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trialImproved malaria case management through the implementation of a health facility-based sentinel site surveillance system in UgandaIntermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, UgandaProtective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trialSurveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serologyMalaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.Why is malaria associated with poverty? Findings from a cohort study in rural Uganda.The evidence for improving housing to reduce malaria: a systematic review and meta-analysisDetermining health-care facility catchment areas in Uganda using data on malaria-related visits.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataArtemisinin combination therapies for treatment of uncomplicated malaria in Uganda.Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda.Sex Disparity in Cord Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero.Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.Long-lasting insecticide-treated bed net ownership and use among children under five years of age following a targeted distribution in central UgandaAn artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia.Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren.Low-Quality Housing Is Associated With Increased Risk of Malaria Infection: A National Population-Based Study From the Low Transmission Setting of Swaziland.The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from UgandaPlasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virusLikely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey.Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan childrenEffect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistanceAcute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria.Assessing the quality of tuberculosis evaluation for children with prolonged cough presenting to routine community health care settings in rural UgandaArtemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenIncreased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.PCR-based pooling of dried blood spots for detection of malaria parasites: optimization and application to a cohort of Ugandan childrenPolymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Loss and dysfunction of Vδ2⁺ γδ T cells are associated with clinical tolerance to malaria.Indoor residual spraying of insecticide and malaria morbidity in a high transmission intensity area of Uganda.
P50
Q24815752-70AB9EDD-DF29-4F14-A5C4-77921944F0F9Q26783902-4E911658-557D-4F6E-B515-9B2FD09099C7Q27861962-3A9C07D6-8840-4178-89FA-B9DE601B96B0Q28125904-D9E3D315-841C-4368-BDE3-FAB9DDFB5987Q28263182-EEC276D0-2CEC-4CD3-88CB-55106B2BF064Q28469217-A2A161C3-12A1-44DE-AD0D-5551580BB150Q28476776-BACE9EE9-5F4E-40E1-8983-8FF3A0C5DAC6Q28536733-93F0901A-C920-453B-B015-C78550C06A54Q28541598-E5C106B7-568F-4DE4-8322-6543592C5BA2Q28740283-C8369558-4627-4640-8868-802867A9B966Q30226671-512771BD-2184-48F9-BD70-25140CF26514Q30382407-7CF8D7EB-5463-487F-B494-D9EFEF973214Q30388585-3CA12BB9-D993-4363-98BD-117F0F2DAFD9Q30793616-B20C8F44-971F-473F-AB37-912F0E62B3E1Q30936416-FBD281E3-B133-4126-B748-763F4155371BQ33251914-A7C9321C-404C-4E5E-9640-9804696D1632Q33342827-ECD4758D-16B0-4EFF-813C-D08541536A22Q33399342-850695F9-0584-403A-A383-291AC7C01EB5Q33489551-BBD16F10-AE3F-4BAF-889F-C5706C41345CQ33559051-6B2CD304-43E0-4921-B37A-F9078F86A2A5Q33629027-1A2CED3E-7217-4BC2-8AD2-F2933976A427Q33629511-A743A76F-73F4-41BF-A7E3-FE217891D498Q33650896-F69318D8-D6EC-4A58-9779-6644052B3360Q33673523-CEFCF2C3-927E-497F-8DF5-DBA6838194DCQ33678775-F77103E8-17F6-4431-B49B-E23498B7C042Q33728165-3973D8A7-080B-441F-B44F-92A38F00991CQ33736395-D0C55F4F-0F7C-4D02-9871-A90ABFBC3E2CQ33805240-C39C3BEC-0B43-4BB8-93BE-6B4149D50249Q33817605-988746FA-31F3-4B27-9897-840A252105CEQ33842153-75A57F0D-E295-4161-9EF8-38C224056957Q33947834-7CBDD69D-FE70-474E-B3A9-57E38246FD1FQ33992235-C43186E7-F058-47F0-BFCD-6735FFA5D75BQ34019213-DD97BB05-D2CF-4777-9048-19D0A1504122Q34110262-55721E5F-AE76-41FA-B675-8CA38C0EC29DQ34137766-A1E9DD70-075B-4575-B01A-33052AEC0944Q34160147-69052F4E-EA46-4AC9-A795-B6D1B8647E4AQ34190509-21AC5733-B413-4CA3-999E-F1EC30D232A6Q34281680-525C5691-7F17-4EE4-BCEF-17B1AD8FB26AQ34343795-35CDA131-3C14-419D-9A8F-579578166401Q34374809-53EC2064-B4CE-4662-9F5C-50641379AC7B
P50
description
researcher ORCID ID = 0000-0003-0740-0317
@en
wetenschapper
@nl
name
Grant Dorsey
@ast
Grant Dorsey
@en
Grant Dorsey
@es
Grant Dorsey
@nl
type
label
Grant Dorsey
@ast
Grant Dorsey
@en
Grant Dorsey
@es
Grant Dorsey
@nl
prefLabel
Grant Dorsey
@ast
Grant Dorsey
@en
Grant Dorsey
@es
Grant Dorsey
@nl
P106
P21
P31
P496
0000-0003-0740-0317